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Abstract
Background: The CD40-CD40L (CD154) costimulatory
pathway plays a critical role in the pathogenesis of kid-
ney allograft rejection. In renal transplant biopsies,
CD4+CD40L+ graft-infiltrating cells were detected during
chronic rejection in contrast to acute rejection episodes.
Using a rapid noninvasive FACS procedure, we were
able to demonstrate CD40L upregulation in peripheral
blood of patients with chronic renal allograft dysfunc-
tion. Materials and Methods: Whole blood from recipi-
ents of renal allografts was stimulated with PMA and ion-
omycin and measured by flow cytometry. Patients were
assigned to three groups based on transplant function.
Group 1: 26 patients with excellent renal transplant func-
tion; group 2: 28 patients with impaired transplant func-
tion; group 3: 14 patients with chronic allograft dysfunc-
tion and group 4: 8 healthy controls. Results: The median
percentage BSEM of CD4+/CD40L+ cells stimulated ex
vivo at 10 ng/ml PMA was as follows: group 1: 28.3 B
4.1%; group 2: 18.4 B 2.4%; group 3: 50.1 B 5.0% and
group 4: 40.4 B 3.4%. Subdivisions of groups 2 and 3
resulted in different CD40L expression patterns. Patients
with increased serum creatinine since the initial phase
after transplantation (groups 2a and 3a) revealed a high-
er percentage of CD4+CD40L+ cells than patients show-
ing a gradual increase over time (groups 2b and 3b).
Consequently, patients of group 3a exhibited a signifi-
cantly reduced transplant function compared with those
of group 3b. Conclusion: After PMA + ionomycin stimula-
tion, patients with excellent kidney graft function dis-
played significantly reduced expression of CD40L sur-
face molecules on CD4+ cells early after transplantation.
Those with a chronic dysfunction of the renal graft
showed significantly more CD4+ cells expressing CD40L
compared to the other transplanted groups. These re-
sults demonstrate that the percentage of CD4+CD40L+
cells stimulated ex vivo in peripheral blood may be a
valuable marker for chronic allograft nephropathy.
Copyright © 2004 S. Karger AG, Basel
Introduction
Despite improvements in 1-year allograft survival, the
long-term results of kidney transplantation remain unsa-
tisfactory with an average half-life of approximately 14
years. A multitude of risk factors has been defined and
correlated with allograft failure. One major reason for ear-
CD40L Expression in Chronic Allograft
Dysfunction
Int Arch Allergy Immunol 2004;133:276–284 277
ly graft loss is persistent immunological stress. To date,
the underlying pathological mechanisms of this condition
are incompletely understood. Intimal thickening of ves-
sels, tubular atrophy, glomerulosclerosis and interstitial
fibrosis are unspecific histopathologic features of chronic
allograft nephropathy, which are similar to those of ath-
erosclerotic lesions.
In general, renal allografts are rejected as a result of an
immune response directed at alloantigens expressed on
the graft. In this respect, the role of HLA antigens is well
established. Various investigators have demonstrated that
early and late acute rejection episodes represent major
causes of chronic graft dysfunction and subsequent graft
loss. Apart from immunological processes, nonimmuno-
logical risk factors account for chronic allograft dysfunc-
tion as well. Putative nonimmunological risk factors in-
clude donor age, donor source (living or cadaveric), cold
ischemia time, delayed graft function, size mismatch,
donor and recipient gender, recipient race, hyperlipid-
emia and hypertension [1].
The mechanisms by which these clinical risk factors
damage the nephron are not known. Differential intra-
graft gene expression of cytokines, chemokines and their
receptors as well as cytotoxic attack molecules was de-
tected during acute rejection episodes [2, 3]. Nonetheless,
only few data have been published on the role of these
molecules in chronic graft dysfunction. A strong correla-
tion between TGF-ß mRNA expression and the extent of
interstitial fibrosis, a hallmark of chronic rejection has
been described. Hyperexpression of TGF-ß1 is thought to
coincide with chronic allograft nephropathy [4].
More interestingly, a differential expression pattern of
costimulatory molecules has been detected by immuno-
histological staining during acute and chronic rejection
episodes in renal biopsies. In this respect, the CD28/
CTLA-4-B7 pathway appears to be involved mainly in
acute rejection episodes, whereas the CD40-CD40L path-
way seems to be predominant in chronic renal allograft
rejection [5, 6]. The interaction between the B7-1 and B7-
2 receptors, expressed on the surface of antigen-present-
ing cells (APC), and their counter-receptors CTLA-4 and
CD28 presented on T-cells triggers a decisive costimulato-
ry signal for T-lymphocytes that acts in concert with the
interaction between MHC-II and TCR-CD3 [7, 8]. T-lym-
phocyte stimulation by B7-1 and B7-2 and by antigen rec-
ognition induces the expression of the surface molecule
CD40L, a 39-kD type II membrane glycoprotein ex-
pressed mainly on activated CD4+ T-cells, but also on a
small population of CD8+ T-lymphocytes at a low density
[9]. Additionally, it is also found on human dendritic cells
[10], macrophages [11], tissue mast cells, blood basophils
[12], eosinophils [13] and in kidney tissue in inflammato-
ry renal disease [14, 15]. CD40L binds to CD40 present
on B-cells, dendritic cells, activated macrophages and
endothelial cells and thereby activates the immune sys-
tem. Thus CD40-CD40L interactions play a critical role
in the immunologic response. Experimental blockade of
ligation prevents T-and B-cell activation and induces
long-term allograft survival [16–18].
The aim of our study was to measure CD40L expres-
sion on peripheral CD4+ T-cells stimulated ex vivo in
recipients with either excellent function or chronic dys-
function of their renal allografts. In order to determine
this upregulation of CD40L on peripheral blood cells, a
FACS analysis procedure was developed.
Materials and Methods
Patients
This study included 68 patients (41 males, 27 females, mean age
48.5 B 10.0 years), 22 recipients of cadaver kidney transplants (15
males, 7 females, mean age 55.1 B 11.5 years) and 46 recipients of
simultaneous kidney/pancreas transplants (26 males, 20 females,
mean age 45.3 B 7.3 years). The underlying renal diseases were as
follows: diabetes mellitus (n = 47), glomerulonephritis (n = 8), poly-
cystic kidney disease (n = 6), interstitial nephritis (n = 4), analgetic
nephropathy (n = 1), kidney atrophy (n = 1) and 1 undefined cause.
Immunosuppression consisted of cyclosporin A (C) alone, in combi-
nation with mycophenolate mofetil (M), azathioprine (A), steroids
(S) or tacrolimus (T) in combination with mycophenolate mofetil,
azathioprine and steroids. The following regimens were applied:
13 ! C monotherapy; 10 ! C/A; 4 ! C/A/S; 14 ! C/M; 7 ! C/M/S;
1 ! C/S; 2 ! T/A; 12 ! T/M; 1 ! T/S 1 ! T/A/S, 1 ! T/M/S and
2 ! M/S. The mean dosage of immunosuppressants is shown in
table 1. Eight healthy volunteers (4 males, 4 females, mean age 49.2
B 12.4 years) without clinical or laboratory signs of kidney disease
served as controls.
Patients were assigned to three groups based merely on serum
creatinine (s-crea) levels. Group 1 consisted of 26 patients with ex-
cellent renal transplant function ascertained by a stable s-crea of
1.2 mg/dl or less for the whole transplantation period. Group 2 com-
prised 28 recipients with impaired transplant function expressed by
s-crea between 1.5 and 2.4 mg/dl when included in the study and a
s-crea of ^1.8 mg/dl within the first 6 months after transplantation.
Group 3 included 14 patients with consistently elevated s-crea levels
of 62.0 mg/dl defined as chronic allograft dysfunction. Healthy con-
trols (n = 8) were assigned to group 4 (table 2).
None of the patients showed signs of acute rejection of the renal
and/or the pancreatic graft at the time of examination. In order to
exclude inflammatory reactions, the serum levels of c-reactive pro-
tein (CRP) were measured using a highly sensitive assay. Patients
with values higher than 0.5 mg/dl were excluded from the study. No
evidence of bacterial or viral infections was observed when blood
samples were taken (table 3).
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Table 1. Mean (BSEM) dosage of immunosuppressants (mg/kg body weight/day; number of patients in paren-
theses)
Group Cyclosporin A Mycophenolate
mofetil
Azathioprine Tacrolimus Steroids
1 3.15B0.94 (15) 18.85B7.49 (12) 0.80B0.14 (5) 64.52B23.87 (10) 0.16B0.14 (6)
1.1 3.00B0.41 (6) 19.20B8.31 (9) 0.90B0.08 (2) 66.57B24.32 (9) 0.11B0.05 (2)
1.2 3.22B1.10 (9) 17.93B4.53 (3) 0.73B0.13 (3) 46.15B0.00 (1) 0.19B0.16 (4)
2 2.94B0.88 (23) 21.16B7.10 (14) 0.67B0.28 (10) 56.23B6.07 (5) 0.03B0.01 (4)
2a 2.93B0.92 (12) 22.64B7.45 (7) 0.59B0.18 (7) 55.59B6.63 (4) 0.03B0.01 (3)
2b 2.96B0.82 (11) 19.43B6.24 (7) 0.85B0.38 (3) 58.82B0.00 (1) 0.04B0.00 (1)
3 2.64B1.23 (11) 14.31B5.36 (10) 0.73B0.10 (2) 78.50B22.95 (2) 0.10B0.13 (7)
3a 2.01B0.45 (5) 16.31B2.30 (5) (0) 101.45B0.00 (1) 0.04B0.02 (3)
3b 3.06B1.39 (6) 12.70B6.46 (5) 0.73B0.10 (2) 55.56B0.00 (1) 0.14B0.16 (4)
Table 2. Patient demographics of the renal transplant groups (mean B SD)
Group n m/f K-/
KP-Tx
Recipient
age, years
Time after
Tx, years*
s-crea
mg/dla
s-crea
mg/dlb
s-crea
increment %**
1 26 14/12 7/19 49.0B10.5 5.7B4.4 1.2B0.2 1.2B0.2 0.6B12.3
2 28 18/10 9/19 48.6B10.0 8.3B4.3 1.4B0.3 1.8B0.4 31.7B25.5
3 14 9/5 6/8 47.1B8.8 6.8B4.6 1.7B0.6 2.5B0.5 66.0B73.8
4 8 4/4 49.2B12.4 1.0B0.1
Time after Tx
1.1 16 !5 years 47.6B10.7 3.0B1.3 1.1B0.2 1.1B0.2 1B13.6
1.2 10 15 years 51.3B9.8 10.1B4.0 1.2B0.2 1.1B0.1 –1.9B9.1
s-crea increment
2a 16 !30% 48.7B11.0 8.0B4.4 1.5B0.2 1.7B0.2 14.7B9.8
2b 12 130% 48.6B8.4 9.0B4.0 1.3B0.3 2.0B0.4 54.2B22.3
3a 6 !15%c 47.7B10.1 3.7B2.2 2.3B0.2 2.4B0.3 2B6.4
3b 8 150%c 46.7B7.7 9.1B4.6 1.3B0.3 2.6B0.6 112.3B67.1
a Measured after a follow-up of 6 months after transplantation.
b Measured on the day of study.
c There were no patients with s-crea increments between 15 and 50%.
p values: * time after Tx: 1 versus 2, 2a versus 3a, 3a versus 3b and 2b versus 3a (!0.05); ** s-crea increment: 1 versus 2, 1 versus 3, 2a
versus 3a and 2b versus 3b (!0.0005), 2a versus 2b, 3a versus 3b, 2b versus 3a and 2a versus 3b (!0.005).
Stimulation of T-Cells in Whole Blood
For the determination of CD40L cell surface expression, lithium
heparin anticoagulated peripheral blood (not older than 5 h) was
stimulated with calcium ionophore A23187 (ionomycin, hemical-
cium salt, 300 ng/ml final concentration, Sigma, Deisenhofen, Ger-
many) and various concentrations of phorbol-12-myristate-13-ace-
tate (PMA; Sigma). 800 Ìl ionomycin containing RPMI-1640 (+L-
glutamine, Life Technologies, Paisley, UK) was prepared per well
(24-well cell culture cluster, FB, Corning, N.Y., USA). PMA was add-
ed at the following final concentrations: 0, 2, 4, 5, 7.5, 10, 20, 30, 50
and 100 ng/ml. 200 Ìl of whole blood was added to each well and
incubated for 4 h at 37°C in 5% CO2. After thorough washing (0.5%
BSA/PBS, Paesel + Lorei, Hanau, Germany), cells were labeled with
the following monoclonal antibody preparations (PharMingen, Hei-
delberg, Germany, 2 Ìl each): anti-CD40L-PE (TRAP-1), CD8-FITC
(RPA-T8) and CD3-APC (UCHT1) at room temperature in the dark
for 20 min. The red blood cells were lysed by FACSlyse (Becton Dick-
inson, Heidelberg, Gemany), washed and lysed again when neces-
sary. After washing, cells were fixed in 1% paraformaldehyde/PBS
and stored overnight at 4°C pending analysis by flow cytometry.
CD40L Expression in Chronic Allograft
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Fig. 1. FACS gating strategy on peripheral T-lymphocytes stimulat-
ed ex vivo by three-color flow cytometry (CD3-APC, CD8-FITC,
CD40L-PE) shown in a healthy control. CD40L expression on CD4+
T-cells was determined by the following negative selection strategy
using two gates: the first around the lymphocyte population (FSC
versus SSC, R1), the second gate around CD3+CD8– cells (correlat-
ing with CD4+ cells, R2). Events registered in R1 and R2 were ana-
lyzed for CD40L expression.
Table 3. Patient demographics of the renal transplant groups (mean B SD)
Group Preformed
antibodies
% (mean)
HLA-mismatch
HLA-A HLA-B HLA-DR
Cold
ischemia
time, h
Duration
of dialysis
years
Donor
age
years
Acute rejec-
tion/CMV
infectiona
1 4.2 0.8B0.7 1.5B1.0 1.3B1.0 18.1B6.9 4.0B3.4 28.4B12.2 3/4
1.1 0.0 0.9B0.8 1.2B0.8 1.1B1.0 17.9B7.6 4.3B3.9 30.4B11.1 2/1
1.2 6.0 0.7B0.7 2.1B1.0 1.6B1.0 18.7B4.5 3.4B1.6 23.2B13.3 1/3
2 5.8 1.2B0.8 1.5B1.1 1.4B0.9 16.3B7.7 3.8B3.5 31.0B11.8 5/2
2a 4.9 1.5B0.6 1.3B1.0 1.4B0.8 15.9B8.4 3.9B4.0 29.9B10.4 3/0
2b 6.9 0.9B0.9 1.8B1.1 1.4B1.0 16.9B6.5 3.6B2.6 32.5B13.2 2/2
3 3.5 0.8B0.8 1.2B0.8 1.5B0.8 16.8B7.7 3.5B3.8 40.5B14.8 6/4
3a 0.0 1.1B0.7 1.4B0.8 1.7B0.5 17.2B4.6 5.0B1.7 49.0B14.4 2/1
3b 5.8 0.7B0.8 1.1B0.9 1.3B0.9 16.6B9.2 2.5B4.4 35.1B12.4 4/3
a Patients with acute rejection or CMV infection on the day of the study were excluded.
Stimulation of Purified Cells
Naive CD4+ T-cells were sustained by a negative isolation tech-
nique. Using antibody mix and magnetic beads (Dynabeads®, Dynal,
Hamburg, Germany), cytotoxic T-cells, B-cells, NK-cells and mono-
cytes were depleted. Therefore, PBMC were obtained by Ficoll-
Paque (Amersham Pharmacia Biotech AB, Uppsala, Sweden) densi-
ty centrifugation of 30 ml peripheral blood anticoagulated with lithi-
um heparin (1:2 in PBS). After two washing steps with 0.1% BSA/
PBS, the PBMC were incubated for 20 min at room temperature with
the following antibody preparations (PharMingen, 40 Ìl each): anti-
CD8 (PRA-T8), -CD14 (M5E2), -CD16 (3G8), -CD19 (HIB19),
-CD56 (B159). After washing, Dynabeads® were added followed by a
15-min incubation at 4°C. The tube was then placed in a Magnetic
Particle Concentrator (Dynal) for 2 min and supernatant (negatively
isolated CD4+ T-cells) pipetted into a fresh tube. The same proce-
dure was applied in order to obtain CD4+ T-cells, monocytes and
B-cells in one tube using only anti-CD8, -CD16 and -CD56 mAbs.
Cells were stimulated by transferring 7 ! 104 cells/well/ml and using
different concentrations of ionomycin (0–400 ng/ml), PMA (0–100
ng/ml) and stimulation intervals as already described in detail.
Flow Cytometric Analysis
Data were collected with a FACSCalibur (Becton Dickinson
Immunocytometry Systems, San Jose, Calif., USA) flow cytometer
and analyzed by using Cellquest software (Becton Dickinson Immu-
nocytometry Systems). 8,000 lymphocytes were counted by using a
gate around the lymphocyte population on a forward scatter versus
side scatter dot-plot. Another gate was set on CD3+CD8– cells (cor-
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Fig. 2. Ex vivo stimulation: surface CD40L expression of the three
renal transplant groups; ) = group 1, patients with excellent renal
transplant function; P = group 2, patients with impaired graft func-
tion; d = group 3 patients with chronic allograft dysfunction
expressed as median B SEM. Whole blood was incubated with 300
ng/ml ionomycin and different concentrations of PMA (0–100 ng/
ml). CD4+/CD40L+ T-cells were detected by using a negative selec-
tion strategy; a subpopulation of CD3+ T-lymphocytes (CD3+CD8–
T-cells) was gated and CD40L expression was detected on those
‘CD4+’ T-cells. p values at 2 ng PMA: 1 versus 3 = 0.0159, 2 versus
3 = 0.0007; p values at 10 ng PMA: 1 versus 3 = 0.0055, 2 versus.
3 = 0.0001.
Fig. 3. CD40L expression in group 1 patients. The group was subdi-
vided in patients who had been transplanted less than 5 years ago
(group 1.1; $) and those with a longer duration (group 1.2; o) mea-
sured under the same conditions as depicted in figure 2. p values at
2 ng PMA: 1.1 versus 1.2 = 0.0398.
relating with CD4+ cells and hence termed as CD4+ cells), because
PMA and ionomycin reduced the level of CD4 expressed on T-cells,
preventing its use as a positive selection marker [19]. This negative
selection strategy displayed the results as the percentage of CD40L+
cells that were CD3+CD8– cells activated in vitro. In order to dis-
criminate between positive and negative fluorescence, an IgG1-PE
isotype control monoclonal antibody (PharMingen) was used. The
cells expressing fluorescence greater than the isotype control were
identified as the percentage of CD40L+ cells (fig. 1). The term CD4+/
CD40L+ describes CD4+ T-lymphocytes (setting 100%) concomi-
tantly expressing CD40L [20].
Statistical Analysis
All CD40L values were calculated as median B SEM. Differ-
ences among the results of experimental treatments were evaluated
by Kruskal-Wallis and Mann-Whitney U test, performed with
BMDP statistical software (BioMeDical Programs, Cork, Ireland).
p ! 0.05 generated at 2 and 10 ng PMA concentrations were consid-
ered to be significant.
Results
Expression of CD40L on Stimulated Peripheral
T-Cells from Patients after Renal Transplantation
Patients with excellent and those with impaired renal
graft function (groups 1 and 2) showed similar percent-
ages of CD4+/CD40L+ cells (at 10 ng PMA; 28.3 B 4.1
and 18.4 B 2.4%). Patients with chronic allograft dys-
function (group 3) displayed a significantly higher per-
centage of CD4+ lymphocytes expressing CD40L (50.1 B
5.0%, p value !0.01) (fig. 2). Healthy controls showed
similar CD40L expression patterns than group 3 patients
(40.4 B 3.5%). Furthermore, CD40L expression on
CD8+ T cells in patients with chronic allograft dysfunc-
tion was higher than in groups 1 and 2 (9.4 B 1.4 versus
7.7 B 0.9% and 7.2 B 0.5%, p ! 0.05). The percentage in
healthy subjects was 8.9 B 0.6%.
CD40L expression did not correlate with age, sex and
the immunosuppressive regimens of transplant recipients
(table 1).
Subdivision of Group 1 after Transplant Duration
In patients with stable graft function (group 1) the per-
centages of CD4+/CD40L+ cells stimulated ex vivo var-
ied considerably. Thus this transplant population was
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Fig. 4. Surface CD40L expression in subgroups: group 2a ()) and
group 3a ([): patients with already initially raised s-crea levels and
group 2b ($) and group 3b (P): patients with gradually increasing
s-crea. Because of a better perceptibility at lower PMA concentra-
tions, CD4/CD40L levels were depicted only from 0 to 50 ng/ml
PMA. p values at 2 ng PMA: 2a versus 3a = 0.0356, 2b versus 3a =
0.0066, 2b versus 3b = 0.0030; p values at 10 ng PMA: 2a versus 2b =
0.0322, 2a versus 3a = 0.0064, 2a versus 3b = 0.0239, 2b versus 3a =
0.0016, 2b versus 3b = 0.0009.
Fig. 5. CD40L expression on T-helper cells in normal subjects after
ex vivo stimulation of whole blood – dose response for ionomycin.
Blood was incubated at 37°C for 4 h with 6 different concentra-
tions of ionomycin [0 (d), 50 ()), 100 (P), 200 (o), 300 ($) and
400 ng/ml ([) ionomycin] and 10 different concentrations of PMA. 
subdivided into two subgroups. Those patients with a
graft transplanted less than 5 years ago (group 1.1, mean
Tx time 3.3 B 1.3 years) and those with a graft trans-
planted longer than 5 years ago (group 1.2, mean Tx time
10.1 B 4.0 years). Whereas only a few cells were positive
for CD40L in subgroup 1.1 (20.9 B 5.9%), in group 1.2
the level increased significantly to 33.8 B 5.9% (p ! 0.05
at 2 ng PMA) 5 years and longer after transplantation
(fig. 3).
Subdivisions of Groups 2 and 3 after s-crea Increment
Patients with impaired graft function (group 2) and
patients with chronic graft dysfunction (group 3) were
split up into subgroups. Patients with already initially
raised s-crea levels (groups 2a and 3a) displayed a relative-
ly small s-crea increment during the observation time
(14.7 B 9.8 and 4.2 B 6.4%). Those patients with a grad-
ual s-crea increment were assigned to groups 2b and 3b
(s-crea increment 54.2 B 22.3 and 112.3 B 67.1%).
Patients of group 2a and 3a had a higher percentage of
CD4+/CD40L+ cells (27.0 B 3.2 and 54.7 B 7.4) stimu-
lated ex vivo than 2b and 3b patients (13.0 B 3.1 and 41.9
B 6.6%). Kidney graft function of patients in group 3a
was considerably worse than in group 3b patients, where-
as there was almost no difference between group 2a and
2b patients with regard to transplant function (table 2,
fig. 4).
Different CD40L Expression on Whole Blood T-Cells,
Purified CD4+ T-Cells and the Influence of Monocytes
and B-Cells
Stimulation of T-cells in whole blood by PMA and ion-
omycin resulted in a distinct upregulation of CD40L
expression. Ionomycin alone had almost no influence on
CD40L expression in concentrations of 50–400 ng/ml; in
contrast, pure PMA resulted in increased expression at
various concentrations (2–100 ng/ml). Depending on
PMA concentrations (between 2 and 10 ng/ml PMA), a
remarkable early phase decrease in CD40L expression
was observed independent of ionomycin concentrations
(fig. 5). Experiments with purified CD4+ T-cells (nega-
tively selected, 85% purity) showed a strong effect of iono-
mycin on CD40L upregulation. A further increase in
CD40L expression was accomplished by addition of
PMA. The striking initial reduction of CD40L expression
occurring in whole blood could also be detected on puri-
fied CD4+ T-cells (fig. 6). The influence of B-cells and
282 Int Arch Allergy Immunol 2004;133:276–284 Lederer/Friedrich/Gruber/Landgraf/
Toepfer/Sitter
Fig. 6. Influence of PMA and ionomycin on CD40L expression on
enriched peripheral CD4+ T-cells obtained from a normal subject.
Enrichment was performed by negative selection strategy on PBMC
using an antibody mix (anti-CD8, -CD19, -CD14, -CD16 and -CD56
mAb) and Dynabeads® to deplete cytotoxic T-cells, B-cells, NK-cells
and monocytes. Cells were incubated with the same concentrations
of activators as in figure 5. Ionomycin concentration: 0 (d), 50 ()),
100 (P), 200 (o), 300 ($) and 400 ng/ml ([).
Fig. 7. Enriched CD4+ T-cells – kinetic analysis of a normal subject:
Influence of B-cells and monocytes on ex vivo CD40L expression. In
order to determine influence of monocytes and B-cells on CD40L
expression, CD4+ T-cells were incubated with 100 ng/ml ionomycin
and different concentrations of PMA (0–100 ng/ml) for 1 (d), 2 (P),
3 (o), 4 ($), 5 ([) and 22 h ()).
monocytes was studied using PBMC purified from NK-
cells and cytotoxic T-cells. Depending on stimulation
time, CD40L expression increased within 5 h; a decrease
was noticed thereafter (fig. 7).
Discussion
The present study demonstrates that in patients with
well-functioning kidney grafts, CD40L expression on pe-
ripheral T-cells stimulated ex vivo is primarily reduced in
the early course after transplantation, whereas CD40L
expression is heightened in chronic renal allograft dys-
function.
The role of CD40L in the setting of kidney transplanta-
tion is ill-defined. CD40L is not present on resting T-cells;
however, in vivo expression is induced by cross-linking of
antigen receptors with MHC-peptide complexes on APCs.
CD40L is rapidly expressed by engagement of immobil-
ized anti-CD3 mAb to the T-cell receptor (TCR) [21]. In
vitro activation of the TCR can be bypassed by ionomy-
cin which increases the level of intracellular Ca2+ and thus
mimics the effects of inositol 1,4,5-triphosphate (IP3) and
by PMA, an activator of protein kinase C (PKC). Intracel-
lular Ca2+ has been shown to induce high-level expression
of CD40L both at the protein and the mRNA level. Addi-
tional activation of PKC by PMA results in markedly
increased CD40L expression and prolongs the CD40L
mRNA half-life by a mechanism which does not require
de novo protein synthesis [22, 23].
Surprisingly, downregulation of CD40L expression oc-
curred at PMA concentrations of 10 and 30 ng/ml in our
study (fig. 5). Experiments with purified CD4+ T-cells
(fig. 6) revealed the same effect in a diminished amount.
CD40L expression on enriched CD4+ T-cells (PBMC
depleted of NK-cells and cytotoxic T-cells) was deter-
mined in order to investigate the influence of B-cells and
monocytes (fig. 7). As described by Yellin et al. [24] and
van Kooten et al. [25], these cells are able to downregulate
CD40L in a time-dependent manner in order to avoid
excessive and inappropriate B- or T-cell activation. Our
data support this observation. However, from our experi-
ments, the exact mechanisms behind the apparent
CD40L downregulation at 10 and 30 ng/ml PMA concen-
trations remain obscure.
CD40L Expression in Chronic Allograft
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To our knowledge, only one study analyzed CD40L
gene expression in peripheral CD4+ T-cells in the setting
of acute and/or chronic renal allograft rejection [26]. The
results of this study, which used the quantitative reverse
transcription-polymerase chain reaction (RT-PCR) on pe-
ripheral blood CD4+ T-cells, were similar to ours. In
patients with acute rejection and/or chronic allograft ne-
phropathy (CAN), CD40L gene expression, and subse-
quently protein expression on peripheral CD4+ T-lym-
phocytes, were elevated in contrast to patients with excel-
lent allograft function. Successful treatment of acute re-
jection episodes inhibited CD40L gene expression. Levels
of CD40L gene expression significantly correlated with
the tubular, interstitial, vascular and total acute rejection
score. Nonetheless, expression levels did not correlate
with any of the chronic lesions described by the Banff
score system.
Several studies pointed at the crucial role of the CD40-
CD40L pathway in chronic allograft rejection displaying
CD40-CD40L interactions in renal biopsies. Gaweco et
al. [27] reported on an enhanced CD40L expression on
glomerular endothelial, mesangial and epithelial cells and
a moderate CD40L expression on tubular epithelial cells.
Moreover, during chronic rejection, CD40+ cellular infil-
trates were detected consisting of predominantly TCR-·/
ß+ T-cells and to a lesser extent CD68+ macrophages.
These data imply a potential contributory role of an inter-
action between CD40+ graft-destructive effector cells and
macrophages with CD40L+ renal allograft parenchymal
cells in the development of chronic renal allograft rejec-
tion. Biancone et al. [5] observed CD40 expression on
peritubular capillaries and on glomerular endothelium,
whereas CD40L+CD4+ cell infiltrates were present both
in the interstitium and in glomeruli. The interaction of
endothelial-bound CD40 and its ligand induces endothe-
lial cell activation. This event may possibly be involved in
the pathogenesis of chronic vascular rejection [28].
In the present study we were able to demonstrate that
elevated CD40L expression on CD4+ T-cells stimulated
ex vivo correlated with chronic allograft dysfunction. This
effect was most pronounced in patients with initial mal-
function of the transplanted kidney as expressed by signif-
icantly elevated s-crea levels already 6 months after trans-
plantation. One might assume that the biological response
to immunosuppressive agents was reduced in those recipi-
ents. Interestingly, nearly half the patients with stable
allograft function showed heightened CD40L expression.
Most of these patients (7 of 11) had been transplanted
more than 5 years ago. Because of the unavailability of
renal allograft biopsies, we can only speculate about the
underlying causes. Subclinical rejection episodes are a
common phenomenon when serial biopsies are per-
formed [29]. In one series, more than two thirds of stable
grafts displayed upregulation of cytokine transcripts and
histological evidence of injury. The degree of lymphocytic
infiltration correlated with the degree of proteinuria and
histological fibrosis. Subsequently, these patients had a
significantly impaired graft function as determined by s-
crea and GFR. Earlier studies substantiated the signifi-
cant role of subclinical rejection episodes with the devel-
opment of chronic pathology and late graft dysfunction
[30]. With respect to the late onset of these findings we
suspect, along with others [26], that nonimmunological
factors such as hyperlipidemia or CNI toxicity are in-
volved as well. In this setting, CD40L expression might
indicate beginning chronic allograft nephropathy.
Our study emphasizes the important role of heightened
peripheral CD40L expression on CD4+ T-lymphocytes
stimulated ex vivo in the context of chronic renal allograft
dysfunction. Studies with nonhuman primates blocking
the CD40-CD40L or CD28/CTLA-4-B7 costimulatory
pathway have revealed positive effects with respect to
immunosuppressive-free graft survival [16, 31–33]. Acute
rejection episodes were prevented for more than 20
months after drug withdrawal and preliminary data sug-
gest a state of tolerance of graft-infiltrating T- and B-cells
[34].
In summary, further studies are needed in order to
determine whether the blockade of T-cell costimulatory
pathways in humans has the power to selectively prevent
transplant rejection without the need of conventional
immunosuppression. The determination of CD40L ex-
pression on peripheral T-lymphocytes stimulated ex vivo
might have the potential to further promote this thera-
peutic approach. Histopathological studies are clearly
needed to clarify whether CD40L induction on peripheral
T-cells is a function of transplant duration or indicates an
ongoing, pronounced immune response in patients escap-
ing the action of conventional immunosuppressive drugs.
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